GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zenas Biopharma ZBIO · USD

Health Care · US listing · 🇺🇸 United States

Compare

28.57

+1.10%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zenas Biopharma

From its filings with the US Securities and Exchange Commission

SEC filings

Zenas Biopharma is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ZBIO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $10.0m and a net loss of $377.7m. At that date it held total assets of $383.6m and shareholders' equity of $242.1m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Sept 2024
Employees
167
Head office
852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Leon MoulderFounder, Chairman of the Board of Director, Chief Executive Officer, since 2020$20.0m
  • Mr. Joseph FarmerPresident, Chief Operating Officer$6.0m
  • Ms. Jennifer FoxChief Business Officer, Chief Financial Officer$4.7m
  • Dr. Haley LakenChief Scientific Officer
  • Mr. Orlando OliveiraChief Commercial Officer$5.9m
  • Dr. Lisa von MoltkeHead of Research and Development, Chief Medical Officer
  • Ms. Patricia AllenIndependent Director$564,412
  • Mr. James BoylanIndependent Director$494,981
  • Mr. Patrick EnrightIndependent Director$494,981
  • Mr. Tomas KiselakIndependent Director$492,501
  • Ms. Hongbo LuIndependent Director$492,501
  • Mr. Jake NunnIndependent Director$493,668

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
28
Environment
26
Social
35
Governance
23
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Zenas Biopharma Inc employs 167 employees in Waltham, Massachusetts.
  • Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcyRIIb for autoimmune diseases.
  • The company's pipeline includes ZB002, ZB004, ZB001, and ZB005 programs.

Weaknesses

  • Zenas Biopharma Inc has 114 full-time employees as of the IPO date.
  • The company's lead product obexelimab is still in clinical development phase.
  • Zenas Biopharma Inc went public on 13 September 2024 with limited commercial history.

Opportunities

  • Zenas Biopharma Inc targets autoimmune diseases with obexelimab and ZB002 programs.
  • The company's global programs ZB002 and ZB004 could expand into new markets.
  • Zenas Biopharma Inc's pipeline includes regional programs like ZB001 and ZB005.

Threats

  • Zenas Biopharma Inc faces competition in the biotechnology sector.
  • The company's clinical-stage status poses development risks for obexelimab.
  • Zenas Biopharma Inc's IPO on 13 September 2024 may face market volatility.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.